<DOC>
	<DOCNO>NCT00507013</DOCNO>
	<brief_summary>The QuickClose study prospective , non-randomized study , evaluate safety efficacy QuickClose device use two different dose type heat exposure . Patients undergoing diagnostic angiogram procedure treat QuickClose device . Two group 20 patient , enrol consecutively , Group A complete enrollment enrollment Group B begin . Patients monitor 30 day procedure</brief_summary>
	<brief_title>Hemostatic Closure Femoral Artery Access Site , Using QuickClose</brief_title>
	<detailed_description>The primary safety endpoint incidence major complication relate method achieve hemostasis puncture site . The secondary safety endpoint incidence minor complication relate method achieve hemostasis puncture site . The primary efficacy endpoint time hemostasis , time ambulation time discharge . The secondary efficacy endpoint device procedure success .</detailed_description>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>1 . The patient must ≥ 18 year age 2 . The patient guardian must provide write informed consent 3 . The patient must willing comply followup requirement 4 . The patient child bear potential negative pregnancy test within previous 7 day . 5 . Patient eligible day discharge Procedural Inclusion : 1 . A intravascular procedure preform use 6 Fr introducer 2 . The introducer sheath locate common femoral artery 1 . Manual compression preform ipsilateral arterial site within previous 6 week 2 . Any closure device use ipsilateral arterial site within previous 180 day 3 . Any reentry ipsilateral site plan within next 6 week . 4 . History surgical repair blood vessel ipsilateral arterial site 5 . Significant bleeding diathesis platelet dysfunction 1 . Thrombocytopenia ( Plt count ≤ 100,000 ) 2 . Anemia ( Hgb ≤ 10mg/dl and/or Hct ≤ 30mg/dl ) 6 . Has life expectancy le 1 year due terminal illness 7 . Currently treat infection 8 . Receiving GP 2b/3a inhibitor require warfarin therapy within last 14 day . 9 . INR result &gt; 1.2 day procedure 10 . Experienced Myocardial infarction ( CKMB ≥ 2x upper limit normal ) within previous 72 hour 11 . Received thrombolytic within previous 72 hour 12 . Patient currently enrol investigational device drug study endpoint meet . 13 . Absent pedal pulse 14 . Preexisting autoimmune disease ( i.e. , Lupus , Addison 's Disease , Grave 's Disease ) 15 . Has Body Mass Index ( BMI ) &lt; 20 , BMI &gt; 40</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>vascular closure device</keyword>
</DOC>